Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
5.18
-0.27 (-4.95%)
Oct 10, 2025, 3:16 PM EDT - Market open
Atai Life Sciences Revenue
Atai Life Sciences had revenue of $719.00K in the quarter ending June 30, 2025, with 163.37% growth. This brings the company's revenue in the last twelve months to $2.31M, up 510.85% year-over-year. In the year 2024, Atai Life Sciences had annual revenue of $308.00K, down -1.91%.
Revenue (ttm)
$2.31M
Revenue Growth
+510.85%
P/S Ratio
505.91
Revenue / Employee
$42,759
Employees
54
Market Cap
1.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 308.00K | -6.00K | -1.91% |
Dec 31, 2023 | 314.00K | 81.00K | 34.76% |
Dec 31, 2022 | 233.00K | -20.14M | -98.86% |
Dec 31, 2021 | 20.38M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ATAI News
- 9 days ago - Atai Life Sciences: Still A Decent Prospect - But Only Just - Seeking Alpha
- 17 days ago - Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients - Benzinga
- 17 days ago - atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression - GlobeNewsWire
- 4 weeks ago - Atai Life Sciences N.V. (ATAI) Presents at H.C. - Seeking Alpha
- 6 weeks ago - atai Life Sciences to Participate in September Investor Conferences - GlobeNewsWire
- 2 months ago - Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus - Seeking Alpha
- 2 months ago - Why Is ATAI Life Sciences Stock Trading Lower On Monday? - Benzinga
- 2 months ago - ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga